Skip to content

Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types

Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116679
Enrollment
Unknown
Registered
2026-01-13
Start date
2026-01-22
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Microvascular Disease

Interventions

Sponsors

Dongzhimen Hospital, Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. No gender restriction, age 18-85 years; 2. Meet the diagnostic criteria for coronary microvascular disease (IMR >= 30); 3. Have clinical symptoms (tightness, pressure, pain, panic; having one or more of the above symptoms); 4. Subjects are informed and give consent voluntarily, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Acute myocardial infarction within the past 3 months 2.History of acute heart failure episode within the past 3 months 3.Ejection fraction < 40% 4.History of lower extremity arterial stent implantation 5.Complicated by severe valvular stenosis or regurgitation 6.Use of traditional Chinese patent medicines such as Compound Danshen Dripping Pills within the past 3 months 7.Complicated by hyperthyroidism 8.Complicated by lower extremity venous thrombosis 9.Presence of cognitive impairment or inability to cooperate with the investgator 10.Complicated by moderate to severe pulmonary hypertension 11.Complicated by hemorrhagic diseases, currently taking oral anticoagulants, or requiring anticoagulant therapy for existing conditions 12.Newly developed lower extremity venous thrombosis within the past month. 13. Exclude pregnant women, nursing mothers, and individuals with allergies.

Design outcomes

Secondary

MeasureTime frame
Nitric oxide;

Countries

China

Contacts

Public ContactXingxue Pang

Dongzhimen Hospital, Beijing University of Chinese Medicine

20240931524@bucm.edu.cn+86 151 1024 7839

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026